HCP Live October 1, 2023
Tim Smith

This study indicated the potential of PDLs as a strategy for those that have HDHP-HSAs to address both patient access and affordability of asthma care.

A preventative drug list (PDL) is linked with more affordable asthma medication as well as greater use of controller medication, according to recent findings, though PDLs do not lead to differences in outcomes for clinical asthma.1

This new data was the result of a recent case-control study which aimed to assess the effects of a PDL that provides exemption from out-of-pocket cost sharing for patients’ asthma medications on adverse outcomes, on their utilization, and on their out-of-pocket expenses.

The research was viewed as invaluable, given the varying results researchers have had in examining links between...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Survey / Study, Trends
Biotech venture firms continue ‘recalibration’ in third quarter, Pitchbook report finds
Forbes names 30 under 30 in healthcare
Insilico Medicine Launches First-in-Human Trial for AI-Discovered IBD Drug
How to Choose the Right Distribution Partner
Listen: CRISPR history, biotech struggles, & a big week for deals

Share This Article